Melissa Pink Selected Research

Everolimus

1/2018

The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Melissa Pink Research Topics

Disease

5	Neoplasms (Cancer) 01/2018 - 11/2006
1	Hematologic Neoplasms (Hematological Malignancy) 01/2018
1	Lymphoma (Lymphomas) 01/2018
1	Inflammation (Inflammations) 11/2016
1	Parasitic Diseases (Parasitic Disease) 11/2016
1	Medulloblastoma 07/2009

Drug/Important Bio-Agent (IBA)

2	Proteins (Proteins, Gene)FDA Link 11/2016 - 11/2006
1	duvelisibIBA 01/2018
1	Everolimus FDA Link 01/2018
1	Phosphotransferases (Kinase)IBA 01/2018
1	venetoclaxIBA 01/2018
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2018
1	ibrutinibIBA 01/2018
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 11/2016
1	CytokinesIBA 11/2016
1	Programmed Cell Death 1 ReceptorIBA 11/2016
1	AntibodiesIBA 11/2016
1	B7-H1 AntigenIBA 11/2016
1	cyclopamineIBA 07/2009
1	IPI-926IBA 07/2009
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 11/2006
1	Bortezomib (Velcade)FDA Link 11/2006
1	tanespimycin (17AAG)IBA 11/2006
1	Proteasome InhibitorsIBA 11/2006

Therapy/Procedure

2	Therapeutics 01/2018 - 11/2016
1	Immunotherapy 11/2016
1	Oral Administration 07/2009